|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273, e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blechacz B and Mishra L: Hepatocellular
carcinoma biology. Recent Results Cancer Res. 190:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Webb JD, Coleman ML and Pugh CW: Hypoxia,
hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen
sensing. Cell Mol Life Sci. 66:3539–3554. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stegeman H, Span PN, Kaanders JH and
Bussink J: Improving chemoradiation efficacy by PI3-K/AKT
inhibition. Cancer Treat Rev. 40:1182–1191. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang
GF and Jing S: Prognostic significance of HIF-2alpha/EPAS1
expression in hepatocellular carcinoma. World J Gastroenterol.
13:3176–3182. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tong WW, Tong GH, Chen XX, Zheng HC and
Wang YZ: HIF2α is associated with poor prognosis and affects the
expression levels of survivin and cyclin D1 in gastric carcinoma.
Int J Oncol. 46:233–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Putra AC, Eguchi H, Lee KL, Yamane Y,
Gustine E, Isobe T, Nishiyama M, Hiyama K, Poellinger L and
Tanimoto K: The A Allele at rs13419896 of EPAS1 is associated with
enhanced expression and poor prognosis for non-small cell lung
cancer. PLoS One. 10:e01344962015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun HX, Xu Y, Yang XR, Wang WM, Bai H, Shi
RY, Nayar SK, Devbhandari RP, He YZ, Zhu QF, et al: Hypoxia
inducible factor 2 alpha inhibits hepatocellular carcinoma growth
through the transcription factor dimerization partner 3/E2F
transcription factor 1-dependent apoptotic pathway. Hepatology.
57:1088–1097. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ
and Wu C: The correlation of expression levels of HIF-1α and HIF-2α
in hepatocellular carcinoma with capsular invasion, portal vein
tumor thrombi and patients' clinical outcome. Jpn J Clin Oncol.
44:159–167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bruick RK and McKnight SL: A conserved
family of prolyl-4-hydroxylases that modify HIF. Science.
294:1337–1340. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Appelhoff RJ, Tian YM, Raval RR, Turley H,
Harris AL, Pugh CW, Ratcliffe PJ and Gleadle JM: Differential
function of the prolyl hydroxylases PHD1, PHD2 and PHD3 in the
regulation of hypoxia-inducible factor. J Biol Chem.
279:38458–38465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peurala E, Koivunen P, Bloigu R,
Huaapasaari KM and Jukkola-Cuorinen A: Expressions of individual
PHDs associate with good prognostic factors and increased
proliferation in breast cancer patients. Breast Cancer Res Treat.
133:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Michiels C, Tellier C and Feron O: Cycling
hypoxia: A key feature of the tumor microenvironment. Biochim
Biophys Acta. 1866:76–86. 2016.PubMed/NCBI
|
|
17
|
Tanaka T, Torigoe T, Hirohashi Y, Sato E,
Honma I, Kitamura H, Masumori N, Tsukamoto T and Sato N:
Hypoxia-inducible factor (HIF)-independent expression mechanism and
novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
J Cancer Res Clin Oncol. 140:503–513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Su C, Huang K, Sun L, Yang D, Zheng H, Gao
C, Tong J and Zhang Q: Overexpression of the HIF hydroxylase PHD3
is a favorable prognosticator for gastric cancer. Med Oncol.
29:2710–2715. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S, Zhang J, Li X, Luo X, Fang J and
Chen H: The expression of prolyl hydroxylase domain enzymes are
up-regulated and negatively correlated with Bcl-2 in non-small cell
lung cancer. Mol Cell Biochem. 358:257–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Andersen S, Donnem T, Stenvold H, Al-Saad
S, Al-Shibli K, Busund LT and Bremnes RM: Overexpression of the HIF
hydroxylases PHD1, PHD2, PHD3 and FIH are individually and
collectively unfavorable prognosticators for NSCLC survival. PLoS
One. 6:e238472011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gossage L, Zaitoun A, Fareed KR, Turley H,
Aloysius M, Lobo DN, Harris AL and Madhusudan S: Expression of key
hypoxia sensing prolyl-hydroxylases PHD1, −2 and −3 in
pancreaticobiliary cancer. Histopathology. 56:908–920. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui L, Qu J, Dang S, Mao Z, Wang X, Fan X,
Sun K and Zhang J: Prolyl hydroxylase 3 inhibited the
tumorigenecity of gastric cancer cells. Mol Carcinog. 53:736–743.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu QL, Liang QL, Li ZY, Zhou Y, Ou WT and
Huang ZG: Function and expression of prolyl hydroxylase 3 in
cancers. Arch Med Sci. 9:589–593. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xue J, Li X, Jiao S, Wei Y, Wu G and Fang
J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer
cells and inhibits IKKbeta independent of hydroxylase activity.
Gastroenterology. 138:606–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou Y, Liang QL, Ou WT, Liu QL, Zhang XN,
Li ZY and Huang X: Effect of stable transfection with PHD3 on
growth and proliferation of HepG2 cells in vitro and in vivo. Int J
Clin Exp Med. 7:2197–2203. 2014.PubMed/NCBI
|
|
26
|
Henze AT, Garvalov BK, Seidel S, Cuesta
AM, Ritter M, Filatova A, Foss F, Dopeso H, Essmann CL, Maxwell PH,
et al: Loss of PHD3 allows tumours to overcome hypoxic growth
inhibition and sustain proliferation through EGFR. Nat Commun.
5:55822014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Garvalov BK, Foss F, Henze AT, Bethani I,
Gräf-Höchst S, Singh D, Filatova A, Dopeso H, Seidel S, Damm M, et
al: PHD3 regulates EGFR internalization and signalling in tumours.
Nat Commun. 5:55772014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang QL, Li ZY, Zhou Y, Liu QL, Ou WT and
Huang ZG: Construction of a recombinant eukaryotic expression
vector containing PHD3 gene and its expression in HepG2 cells. J
Exp Clin Cancer Res. 31:642012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su Y, Loos M, Giese N, Hines OJ, Diebold
I, Görlach A, Metzen E, Pastorekova S, Friess H and Büchler P: PHD3
regulates differentiation, tumour growth and angiogenesis in
pancreatic cancer. Br J Cancer. 103:1571–1579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
International Union Against Cancer (UICC),
. Sobin LH and Wittekind C: TNM classification of malign ant
tumors. 6th. New York: Wiley-Liss; pp. 81–83. 2002
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
